ArticleNature communications2018
NIR-II nanoprobes in-vivo assembly to improve image-guided surgery for metastatic ovarian cancer.
Article in Nature communications, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 123 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
123 citing papers in PubMed, 1 synthesis or guideline pooled it, 437 citations in OpenAlex.
- Molecular fluorophores for in vivo bioimaging in the second near-infrared window.European journal of nuclear medicine and molecular imaging · 2022Pooled it
- A folate receptor-targeted NIR-II probe improves intraoperative imaging and surgery of metastatic ovarian cancer.Science advances · 2026Article
- Rare-Earth Nanomaterials for Advanced Theranostics of Atherosclerosis.Chemical & biomedical imaging · 2026Review
- Energy loop for afterglow imaging.Nature materials · 2026Article
- Emerging Near-Infrared Targeted Imaging Pharmaceutics for Ovarian Cancer.Pharmaceutics · 2026Review
- Binocular vision fusion enhanced 3D NIR-IIFundamental research · 2026Article
- Real-time near-infrared II fluorescence navigation of magnetic nanorobots for image-guided therapy.Science advances · 2026Article
- Delineating precise surgical resection areas: recent advances in NIR-II fluorescence imaging molecular probes.Frontiers in oncology · 2026Review
- Advancements in Intraoperative Imaging for Enhanced Surgical Precision.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2026Review
- Feasibility of isosulfan blue in sentinel lymph node visualization for gastric cancer.Annals of medicine and surgery (2012) · 2025Article
- Advanced Image-Guidance and Surgical-Navigation Techniques for Real-Time Visualized Surgery.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Micelle-Encapsulated Theranostic Phthalocyanine and Naphthalocyanine Derivatives for Photothermal Therapy and Photoacoustic Imaging with NIR-I vs NIR-II Irradiation.ACS applied nano materials · 2025Article
- Article
- Molecular Gold Nanoclusters for Advanced NIR-II Bioimaging and Therapy.Chemical reviews · 2025Review
- High-contrast in vivo fluorescence imaging exploiting wavelengths beyond 1880 nm.Nature communications · 2025Article
- Molecular probes for in vivo optical imaging of immune cells.Nature biomedical engineering · 2025Review
- Nanodrug Delivery Systems for Acute Lymphoblastic Leukemia Therapy.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Tumor agnostic ultrasmall nanoprobes for fluorescence-guided surgical resection in peritoneal metastasis.European journal of nuclear medicine and molecular imaging · 2025Article
- Tumor Site-Specific In Vivo Theranostics Enabled by Microenvironment-Dependent Chemical Transformation and Self-Amplifying Effect.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Precise Regulations at the Subcellular Level through Intracellular Polymerization, Assembly, and Transformation.JACS Au · 2024Review
63 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
Local recurrence is a common cause of treatment failure for patients with solid tumors. Tumor-specific intraoperative fluorescence imaging may improve staging and debulking efforts in cytoreductive surgery and, thereby improve prognosis. Here, we report in vivo assembly of the second near-infrared window (NIR-II) emitting downconversion nanoparticles (DCNPs) modified with DNA and targeting peptides to improve the image-guided surgery for metastatic ovarian cancer. The NIR-II imaging quality with DCNPs is superior to that of clinically approved ICG with good photostability and deep tissue penetration (8 mm). Stable tumor retention period experienced 6 h by in vivo assembly of nanoprobes can be used for precise tumor resection. Superior tumor-to-normal tissue ratio is successfully achieved to facilitate the abdominal ovarian metastases surgical delineation. Metastases with ≤1 mm can be completely excised under NIR-II bioimaging guidance. This novel technology provides a general new basis for the future design of nanomaterials for medical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.